|
Álvarez-Gutiérrez F.J., Casas-Maldonado F., Valverde-Molina J. News From the Severe Asthma Consensus 2025 Review. Archivos De Bronconeumologia. May 2026. 62:291-293. 10.1016/j.arbres.2025.11.003
AÑO: 2026; IF: 9.2
|
|
Gupta A, de Mir Messa I, Valverde-Molina J, Murray CS, Moral L, Torres Borrego J, Pike K, Diaz-Izquierdo A, Martinez-Canavate A, Nagakumar P, Cook J, Gupta L; CASAM Group. Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM). PLoS One. 2025 Dec 19;20(12):e0335399. doi: 10.1371/journal.pone.0335399. eCollection 2025. PubMed PMID: 41417800; PubMed Central PMCID: PMC12716689.
AÑO: 2025; IF: 2.6
|
|
Almonacid C, Quirce S, Blanco M, Del Cubillo A, Valverde-Molina J, Plaza V. Inside GEMA 5.5: Expert Insights on the Latest Changes in Asthma Management. Arch Bronconeumol. 2025 Dec 2:S0300-2896(25)00418-1. doi: 10.1016/j.arbres.2025.11.011. Online ahead of print. English, Spanish. PubMed PMID: 41421866.
AÑO: 2025; IF: 9.2
|
|
Miralles-Lopez JC, Andujar-Espinosa R, Bravo-Gutierrez FJ, Cabrejos-Perotti S, Ramirez-Hernandez M, Diaz-Chantar C, Pajaron Fernandez MJ, Valverde-Molina J, Perez-Fernandez V; RE-ASGRAMUR GROUP. Tezepelumab in Patients With Severe Asthma: Response at 3 Months. J Investig Allergol Clin Immunol. 2025 Apr 22;35(2):132-134. doi: 10.18176/jiaci.1041. Epub 2024 Nov 25. No abstract available. PubMed PMID: 39584417.
AÑO: 2025; IF: 4.8
|
|
Miralles-López J.C., Bravo-Gutierrez F.J., Andújar-Espinosa R., Castilla-Martínez M., Díaz-Chantar C., Ramírez-Hernández M., Cabrejos-Perotti S., Avilés-Inglés M.J., Ibarra-Calabuig I., Reyes-Cotes M.H., Pajarón-Fernández M.J., Bernabéu-Mora R., Alcalde-Rumayor C., Alemany-Francés M.L., Valverde-Molina J., Pérez-Fernández V. Real-life effectiveness of tezepelumab in severe asthma. Allergologia et immunopathologia. 2025. 53:163-173. 10.15586/aei.v53i2.1326
AÑO: 2025; IF: 2.1
|